Latest Updates

Promising new drug for acute myeloid leukaemia 

A new drug in clinical trials has the potential to improve the survival rate of patients with acute myeloid leukaemia.

Read more

Melanoma revealing its secrets

Professor Nikolas Haass and his team are unlocking the secrets of melanoma cells to identify better treatments for the cancer.

Read more

New drug to beat chemo resistance in ovarian cancer

In a preclinical study, researchers find low doses of a drug can overcome chemotherapy resistance in an ovarian cancer sub-type. 

Read more

An Australian-first initiative of 'bench to bedside' medical research

The Translational Research Institute (TRI) is a unique, Australian-first initiative of ‘bench to bedside’ medical research. TRI combines clinical and translational research to advance progress from laboratory discovery to application in the community.

The work conducted at TRI is translational research, a research process which involves teams of patients, clinicians and researchers working together to solve health challenges faster. The work is driven by the needs of patients, a question formed by a clinician and a solution sought by a scientist.

Find out more

What is Translational Research?

Also known as 'bench-to-bedside' research, it is a type of medical research that focusses on 'translating' basic science discoveries from the laboratory into the clinic.

The aim is to improve how we detect, diagnose and treat health conditions, and improve health outcomes for patients.

At TRI, we work to develop new treatments and diagnostics for conditions ranging from various cancers to autoimmune diseases, and translate these discoveries into improved healthcare.

Find out more

What's On

Wed
5
Aug

COH Telehealth Webinar

In this forum we will discuss how telehealth communities of practice (COP) have been established, how they can...

12:30 pm to 1:15 pm
Thu
6
Aug

Cancer Seminar Series

The Cancer Seminar Series showcases research from our TRI partner institutes- UQ Diamantina, QUT and the Mater and...

9:00 am